Floatz logo

SITOCABNAGENE LOXIVELEUCEL EXPRESSED INDUCIBLE CASPASE-9 COMPRISING HUMAN CASPASE-9 FUSED TO A HUMAN FK506 BINDING PROTEIN VARIANT (FKBP-F36V)

Non-hodgkin Lymphoma

M.D. Anderson Cancer Centerprotein_peptidePhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

411 Active assets in the Non-hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
PEGASPARGASE
Ciusss de L'Est de l'Île de Montréal
Phase 4BBB
Inno-206
National Cancer Institute (NCI)
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Mwanasha Merrill, MD
Phase 3BBB
Entecavir
Fudan University
Phase 4BBB

View all 50 →

Same molecule, other indications

SITOCABNAGENE LOXIVELEUCEL EXPRESSED INDUCIBLE CASPASE-9 COMPRISING HUMAN CASPASE-9 FUSED TO A HUMAN FK506 BINDING PROTEIN VARIANT (FKBP-F36V) is also rated in:

B-cell neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
acute lymphoblastic leukemiaDormant
CCC
Indicative ·
50 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →